Video

Dr. Ornstein on antibody-drug conjugates for immunotherapy-refractory urothelial carcinoma

Author(s):

Urology Times staff

“The management of patients with advanced urothelial carcinoma whose cancer has progressed on immunotherapy presents a unique challenge,” says Moshe Ornstein, MD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the emergence of antibody-drug conjugates as a treatment option for patients with immune checkpoint inhibitor–refractory advanced urothelial carcinoma.

      Related Videos
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
      Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
      Urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Expert describes implications of neoadjuvant durvalumab approval in MIBC
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      How rBCG EAP could open up access for Anktiva in bladder cancer
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
      Related Content
      Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
      April 29th 2025

      Cxbladder Triage may help patients avoid unnecessary cystoscopies

      Benjamin P. Saylor
      The study population was able to avoid 952 cystoscopies and 71 CT scans, according to the investigators.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Sandip M. Prasad, MD, MPhil
      April 27th 2025

      UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC

      Benjamin P. Saylor
      "I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
      December 7th 2021

      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

      Urology Times staff
      “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
      Mark D. Tyson II, MD, MPH
      April 27th 2025

      Cretostimogene yields high CR rate in BCG-unresponsive NMIBC

      Benjamin P. Saylor
      "97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.
      Neal D. Shore, MD, FACS
      April 26th 2025

      CREST: Significant EFS boost seen with sasanlimab plus BCG in NMIBC

      Benjamin P. Saylor
      “In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.
      © 2025 MJH Life Sciences

      All rights reserved.